Peptide‐based supramolecular therapeutics (PST) refer to those theranostic nanomedicines
based on peptide or peptide derivatives self‐assembly that are constructed in vitro or in vivo …

Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80
years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range …

Cancer is a known deadliest disease that requires a judicious diagnostic, targeting, and
treatment strategy for an early prognosis and selective therapy. The major pitfalls of the …

Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ)
radiation through radiation decay. Therefore, they are used in the biomedical field to label …

With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear
medicine as valuable diagnostic or treatment option, radiobiology plays an important role in …

Radiation therapy (RT) is a pillar of cancer therapy used by more than half of all cancer
patients. Clinically, RT is mostly delivered as external beam radiation therapy (EBRT) …

Cyclin-dependent kinase 19 (CDK19) is overexpressed in prostate cancer, making it an
attractive target for both imaging and therapy. Since little is known about the optimized …

Recent research has demonstrated and consolidated the use of TRNT against well
established targets in neuroendocrine tumours and prostate cancer. The identification of …

Radiopharmaceutical therapy (RPT), with its targeted delivery of cytotoxic ionizing radiation,
demonstrates significant potential for treating a wide spectrum of malignancies, with …

Abstract Purpose of Review [177Lu] Lu-PSMA-617 is a radiopharmaceutical that emits beta-
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …